FDA extends eribulin PDUFA date

FDA extended the PDUFA date for an NDA from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) for eribulin mesylate by three months to Dec. 30 from Sept. 30. The NDA is under Priority Review to treat locally ad...